Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on July 30, 2015. The filing serves to announce the company's financial results for the second quarter ended June 30, 2015. The full details of these results are contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached Exhibit 99.1 (Earnings Press Release), which is not included in the source text.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing text. The document solely references the issuance of the Q2 2015 earnings press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section. It further states the information is not incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release dated July 30, 2015) for actual Q2 2015 financial figures.
- Verify the company's name change status, as the filing lists "Pacira Pharmaceuticals, Inc." while the request metadata indicates "Pacira Biosciences, Inc."
- Confirm the specific revenue and net loss figures for the quarter ended June 30, 2015, as they are not present in the 8-K body.
- Check for any forward-looking statements or updated guidance contained within the referenced press release.